Provided by Tiger Fintech (Singapore) Pte. Ltd.

Klotho Neurosciences, Inc.

0.9418
-0.0092-0.97%
Pre-market: 0.94180.00000.00%06:08 EDT
Volume:1.13M
Turnover:1.07M
Market Cap:49.64M
PE:-2.73
High:0.9821
Open:0.9800
Low:0.9300
Close:0.9510
52wk High:3.91
52wk Low:0.1135
Shares:52.70M
Float Shares:40.08M
Volume Ratio:1.10
T/O Rate:2.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3455
EPS(LYR):-0.3195
ROE:-1544.44%
ROA:-151.41%
PB:77.71
PE(LYR):-2.95

Loading ...

Company Profile

Company Name:
Klotho Neurosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
3
Office Location:
13576 Walnut Street,Suite A,Omaha,Nebraska,United States
Zip Code:
68144
Fax:
- -
Introduction:
Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Directors

Name
Position
Joseph Sinkule
Chairman of the Board and Chief Executive Officer
Jon W. Mcgarity
Independent Director
Riad El Dada
Independent Director
Samuel M. Zentman
Independent Director
Shalom Z. Hirschman
Independent Director

Shareholders

Name
Position
Joseph Sinkule
Chairman of the Board and Chief Executive Officer
Peter Moriarty
Chief Operating Officer
Jeffrey Brian LeBlanc
Chief Financial Officer and Principal Accounting Officer